BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America,…
Screened 2026-09-17 · the tape above runs as of 17:00 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
The Label · The Season, Not the Day
This name holds its distribution label.
Biomarin Pharmaceutical Inc holds its Distribution at $65.08. The statistical read favours the sellers, held for 24 days.
As held on the ledger · 2026-09-17
Phase
Distribution · caution
Quantitative state
The statistical read favours the sellers, held for 24 days
Price at the screen
$65.08
Valuation
175.89 trailing · 9.83 forward price to earnings
Values screen
PASS· score 70.0
Beta
0.24
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
7.98%
Below 33%
Interest-bearing debt is just 8.0% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
6.48%
Below 33%
Cash held in interest-bearing accounts and securities is 6.5% of assets, under the one-third limit.
Pass
Receivables
29.23%
Below 49%
Money owed to the company is 29.2% of assets, under the 49% limit.
Pass
Revenue purity
2.33%
Below 5%
Only 2.3% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
Fair value range in USD, drawn from the 2026-09-17 screen. The gold marker is the market price at the same screen. A 72.9% margin of safety to the base estimate.
Third-party analyst targets: 26 covering, consensus Buy. The average target sits +38% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-17 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Rare Disease Biotech at a Discount Price
Picture a specialist biotech firm racing to treat rare diseases, yet posting just 3% revenue growth and an 8% profit margin. BioMarin trades at $59.59 with a forward P/E of 9.3x, but we pass. The narrow moat and 4% ROE signal limited ability to compound capital over time, even with an ethical screen pass and analyst targets around $86.
The 80% gap to our fair value of $107.50 looks tempting at first glance. Yet low single digit growth and thin returns on equity point to a business that struggles to scale its pipeline into durable profits. Consensus buy ratings do not change the underlying economics.
Risks centre on execution in a competitive rare disease space and the narrow moat that leaves room for rivals. Currency moves and regulatory setbacks could further pressure margins. Analysis, not advice.
The risks · The things to watch: as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
BMRN trades on NASDAQ. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-08-23Markup · changed$68.53+15.0%Entry 5
The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 15.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 2%. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (26 analysts) rates it buy, with a mean price target of $88.
The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 6.5% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 2%. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (26 analysts) rates it buy, with a mean price target of $88.
2026-07-18Markup$55.95+0.0%Entry 3
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 2%. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (26 analysts) rates it buy, with a mean price target of $88.
2026-07-03Markup$55.95+0.0%Entry 2
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
2026-07-02Markup$55.95Entry 1
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
